KR101430626B1 - 부프레노르핀 유도체 및 이들의 용도 - Google Patents

부프레노르핀 유도체 및 이들의 용도 Download PDF

Info

Publication number
KR101430626B1
KR101430626B1 KR1020087023692A KR20087023692A KR101430626B1 KR 101430626 B1 KR101430626 B1 KR 101430626B1 KR 1020087023692 A KR1020087023692 A KR 1020087023692A KR 20087023692 A KR20087023692 A KR 20087023692A KR 101430626 B1 KR101430626 B1 KR 101430626B1
Authority
KR
South Korea
Prior art keywords
buprenorphine
compound
salt
formula
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087023692A
Other languages
English (en)
Korean (ko)
Other versions
KR20080105124A (ko
Inventor
크리스토퍼 보룬 차플레오
존 윌리엄 르위스
Original Assignee
알비 파마슈티컬즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알비 파마슈티컬즈 리미티드 filed Critical 알비 파마슈티컬즈 리미티드
Publication of KR20080105124A publication Critical patent/KR20080105124A/ko
Application granted granted Critical
Publication of KR101430626B1 publication Critical patent/KR101430626B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087023692A 2006-03-28 2007-03-27 부프레노르핀 유도체 및 이들의 용도 Expired - Fee Related KR101430626B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0606124.6 2006-03-28
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof
PCT/GB2007/001120 WO2007110636A1 (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
KR20080105124A KR20080105124A (ko) 2008-12-03
KR101430626B1 true KR101430626B1 (ko) 2014-08-18

Family

ID=36384277

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087023692A Expired - Fee Related KR101430626B1 (ko) 2006-03-28 2007-03-27 부프레노르핀 유도체 및 이들의 용도

Country Status (21)

Country Link
US (1) US7964610B2 (enExample)
EP (1) EP2001891B1 (enExample)
JP (1) JP5167446B2 (enExample)
KR (1) KR101430626B1 (enExample)
CN (2) CN104151320A (enExample)
AU (1) AU2007231133B2 (enExample)
BR (1) BRPI0709157A8 (enExample)
CA (1) CA2647417C (enExample)
DK (1) DK2001891T3 (enExample)
ES (1) ES2432169T3 (enExample)
GB (1) GB0606124D0 (enExample)
IL (1) IL193917A (enExample)
MX (1) MX2008011984A (enExample)
MY (1) MY151025A (enExample)
NZ (1) NZ570997A (enExample)
PL (1) PL2001891T3 (enExample)
PT (1) PT2001891E (enExample)
RU (1) RU2435773C2 (enExample)
TW (1) TWI501969B (enExample)
WO (1) WO2007110636A1 (enExample)
ZA (1) ZA200807614B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511054B2 (en) 2006-09-22 2009-03-31 Alltranz Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
PT2307420E (pt) * 2008-04-24 2012-02-14 Janssen Pharmaceutica Nv Pró-fármacos de di-éster de nalmefeno
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
MX2018004835A (es) * 2015-10-26 2018-08-01 Orphomed Inc Etilenglicol eter de buprenorfina.
CA3016510A1 (en) 2016-03-09 2017-09-14 Indivior Uk Limited Abuse-resistant pharmaceutical formulations
CN109789137B (zh) 2016-09-13 2023-01-13 昱展新药生技股份有限公司 丁丙诺啡缓释制剂
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
KR102839314B1 (ko) * 2018-05-11 2025-07-29 에일러 파마슈티컬스 아이엔씨. 오래 지속되는 주사용 제제와 부프레노핀 유도체
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction
CN116283893B (zh) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075361A1 (en) 2002-11-12 2005-04-07 Chi Mei Foundation Medical Center Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (ko) 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
US6225321B1 (en) 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
ES2298323T3 (es) 1998-11-13 2008-05-16 Jagotec Ag Inhalador de polvo seco multidosis con reserva de polvo.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2517710B1 (en) 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
JP2005523876A (ja) 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
AU2003285934A1 (en) * 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
ATE382050T1 (de) * 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US7501113B2 (en) 2003-02-04 2009-03-10 Philip Morris Usa Inc. Aerosol formulations and aerosol delivery of buprenorphine
US7195882B2 (en) 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075361A1 (en) 2002-11-12 2005-04-07 Chi Mei Foundation Medical Center Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions

Also Published As

Publication number Publication date
JP5167446B2 (ja) 2013-03-21
RU2435773C2 (ru) 2011-12-10
CA2647417C (en) 2014-09-23
RU2008142527A (ru) 2010-05-10
MX2008011984A (es) 2008-10-03
EP2001891A1 (en) 2008-12-17
NZ570997A (en) 2011-08-26
TWI501969B (zh) 2015-10-01
CA2647417A1 (en) 2007-10-04
US20100234412A1 (en) 2010-09-16
PT2001891E (pt) 2013-10-30
WO2007110636A1 (en) 2007-10-04
BRPI0709157A2 (pt) 2011-06-28
EP2001891B1 (en) 2013-07-24
AU2007231133A8 (en) 2011-08-25
AU2007231133A1 (en) 2007-10-04
CN104151320A (zh) 2014-11-19
AU2007231133B2 (en) 2011-09-01
JP2009531406A (ja) 2009-09-03
AU2007231133A2 (en) 2008-10-16
PL2001891T3 (pl) 2014-03-31
GB0606124D0 (en) 2006-05-03
IL193917A (en) 2014-12-31
BRPI0709157A8 (pt) 2018-04-24
DK2001891T3 (da) 2013-11-04
CN101410402A (zh) 2009-04-15
ES2432169T3 (es) 2013-12-02
TW200806672A (en) 2008-02-01
KR20080105124A (ko) 2008-12-03
US7964610B2 (en) 2011-06-21
MY151025A (en) 2014-03-31
ZA200807614B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
KR101430626B1 (ko) 부프레노르핀 유도체 및 이들의 용도
KR101795330B1 (ko) 히드로코돈의 벤조산, 벤조산 유도체 및 헤테로아릴 카르복실산 콘쥬게이트, 이의 전구약물, 제조 방법 및 용도
AU2009342654B2 (en) Morphinan derivatives with high oral bioavailability
JP2012254984A (ja) 代謝安定性鎮痛薬、疼痛薬物療法及び他の物質の合成
FI67686B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenetanolaminderivat
US5750534A (en) Nalbuphine esters having long acting analgesic action and method of use
JP2000505448A (ja) カンプトテシン誘導体及び抗腫瘍剤としてのその利用
KR101285645B1 (ko) 진통제
KR20080081057A (ko) 진해제
JPH085863B2 (ja) １４−アニソイルアコニンおよびそれを有効成分とする新規な鎮痛・抗炎症剤
HK1130259A (en) Buprenorphine derivatives and uses thereof
US20200325157A1 (en) Novel Thiophene Compounds for Long-Acting Injectable Compositions and Related Methods
KR100704085B1 (ko) 신규한 부프레노핀 에스테르 유도체, 그의 제조 방법 및지속성 진통제 약학 조성물
JPH092950A (ja) 医薬組成物および処置法
JPH07206672A (ja) 医薬組成物および処置法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20170727

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180809

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180809

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000